The safety of engineered T cells is improved through gated expression of two chimeric antigen receptors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roybal, K.T. et al. Cell 164, 770–779 (2016).
Gross, G. & Eshhar, Z. Annu. Rev. Pharmacol. Toxicol. 56, 59–83 (2016).
Hinrichs, C.S. & Restifo, N.P. Nat. Biotechnol. 31, 999–1008 (2013).
Linette, G.P. et al. Blood 122, 863–871 (2013).
Maude, S.L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).
Obenaus, M. et al. Nat. Biotechnol. 33, 402–407 (2015).
Blankenstein, T., Leisegang, M., Uckert, W. & Schreiber, H. Curr. Opin. Immunol. 33, 112–119 (2015).
Leisegang, M., Kammertoens, T., Uckert, W. & Blankenstein, T. J. Clin. Invest. 126, 854–858 (2016).
Wilkie, S. et al. J. Clin. Immunol. 32, 1059–1070 (2012).
Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Nat. Biotechnol. 31, 71–75 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Blankenstein, T. Receptor combinations hone T-cell therapy. Nat Biotechnol 34, 389–391 (2016). https://doi.org/10.1038/nbt.3539
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3539